Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin
M. Mariniello, R. Petruzzelli, L. Wanderlingh, R. La Montagna, A. Carissimo, F. Pane, A. Amoresano, D. Medina, R. Polishchuk
The paper identifies FDA-approved drugs that overcome ATP7B-mediated cisplatin resistance in ovarian cancer cells through synthetic lethality screening.
bioRxiv · Jul 3, 2019Cancer Biology